Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-14

Study Completion Date

2023-05-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this phase 1 study, the inactivated virus vaccine National Research Centre (NRC) Vaccine-101 (VACC-101) will be investigated for its safety and immunogenicity in healthy volunteers with the aim of providing effective and safe protection against COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine

NCT04747821

Covid19

COMPLETED PHASE4

Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized

NCT05016934

Covid19

WITHDRAWN PHASE1/PHASE2

Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection

NCT05218070

COVID-19

UNKNOWN PHASE1

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

NCT05037097

COVID-19 SARS-CoV-2 Infection Corona Virus Infection

COMPLETED PHASE1/PHASE2

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

NCT04847102

COVID-19 SARS-CoV-2

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase I, Randomized, Open-Labeled Clinical trial. Eligible volunteers will be randomized in a 1:1:1 allocation ratio, into one of the three study arms using the Interactive Web Response Technology (IWRS).

Unscheduled visits can occur at any time during the study period outside the initially planned study visits, all the extra visits will be documented in the subjects' files. Volunteers will be randomized into one of the following arms to receive different doses of the Inactivated

SARS-COV-2 Vaccine "NRC-VACC-101" as an intramuscular (IM) Injection or Placebo:

Arm One:

Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.

Arm Two:

Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.

Arm Three (Control arm):

Volunteers will receive two IM doses of the placebo, 28 days apart. The first 9 subjects will be initially vaccinated with their first dose, as per their assigned study arm determined by the randomization procedures and will be followed up until day 14 (visit 03). At this point in the study, the Data Safety and Monitoring Board (DSMB) will review safety data before proceeding with vaccinating the rest of the recruited subjects

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Vaccine Reaction Vaccine Adverse Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A Randomized, Open-label, Phase 1 Clinical trial.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NRC-VACC-101 vaccine 3 microgram

Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.

Group Type ACTIVE_COMPARATOR

Covi Vax

Intervention Type BIOLOGICAL

Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.

NRC-VACC-101 vaccine 6 microgram

Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.

Group Type ACTIVE_COMPARATOR

Covi Vax

Intervention Type BIOLOGICAL

Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.

Control arm

Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.

Group Type PLACEBO_COMPARATOR

Covi Vax

Intervention Type BIOLOGICAL

Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Covi Vax

Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NRC-VACC-101 vaccine Egyptian Inactivated SARS-CoV-2 Vaccine NRC Inactivated SARS-CoV-2 Vaccine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults with age 18 to 50 years.
2. Willingness.
3. For married females of childbearing age: Willingness to practice continuous effective contraception for one year from the start of the study.
4. Agreement to refrain from blood donation during the study.
5. Body temperature is within the normal range (36.5 - 37.5°C).
6. General good health as established by medical history, physical and laboratory examinations.

Exclusion Criteria

1. Pregnancy or lactation.
2. Inability to provide informed consent.
3. Recent receipt of any vaccination within 30 days prior to baseline.
4. Planning to receive any vaccination during the course of the study.
5. Prior receipt of Adenovirus vaccine, or any other Coronavirus vaccine.
6. Recent receipt of any immunoglobulin within 90 days prior to baseline.
7. Recent receipt of any blood product within 90 days prior to baseline.
8. Volunteers who are immunosuppressed or receiving immunosuppressive medications, including:

HIV infection, asplenia, recurrent severe infections, and the use of immunosuppressive medications within the past 6 months, except for topical steroids or short-term oral steroids (course lasting \< 14 days).
9. Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
10. Having any autoimmune disease.
11. History of allergic reactions for any of the vaccine components.
12. History of angioedema.
13. History of anaphylaxis.
14. History of cancer.
15. History of serious psychiatric conditions that are likely to affect participation in the study.
16. Having bleeding disorders.
17. Having chronic respiratory diseases.
18. Having chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorders, and neurological illness.
19. Volunteers with BMI ≥ 40 Kg/m2 or ≤ 18 Kg/m2.
20. Current alcohol abuse.
21. Drug abuse within 5 years prior to baseline.
22. History of laboratory-confirmed COVID-19 or seropositivity for SARS-CoV-2 or positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) to the SARS CoV-2 or abnormal chest CT-Scan (COVID-19 image) or positive pharyngeal/sputum swabs for SARS-CoV-2.
23. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
24. High-risk population (volunteers who work in front-line health facilities or were in close contact with confirmed COVID-19 cases).
25. Living in the same household as anyone at high risk of severe COVID-19.
26. Any condition, according to the judgment of the investigator, that would interfere with the subject's ability to comply with all study requirements or that would place the subject at unacceptable risk by his/her participation in the study or impair the interpretation of the study data.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes